Prelude Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	21.76	35.26	12.47	25.29	30.61	31.83
Short-Term Investments	59.8	67.96	121.14	207.64	171.12	259.41
Cash & Short-Term Investments	81.55	103.21	133.61	232.94	201.73	291.23
Cash Growth	-17.68%	-22.75%	-42.64%	15.47%	-30.73%	33.40%
Other Current Assets	3.04	2.48	2.28	2.65	2.65	3.88
Total Current Assets	84.59	105.69	135.9	235.59	204.38	295.12
Net Property, Plant & Equipment	31.5	32.28	35.47	37.74	6.7	5.64
Other Long-Term Assets	3.55	3.35	4.15	4.34	9.42	4.35
Total Assets	119.64	141.32	175.52	277.67	220.5	305.1
Accounts Payable	2.07	3.98	7.73	4.58	6.78	7.84
Accrued Expenses	5.94	12.53	15.21	15.77	13.09	9.62
Current Portion of Leases	2.76	2.74	2.7	1.48	1.83	1.74
Unearned Revenue	30.95	33.73	-	-	-	-
Total Current Liabilities	41.72	52.99	25.64	21.83	21.7	19.2
Long-Term Leases	14.96	15.05	15.33	18.75	-	-
Other Long-Term Liabilities	2.78	4.64	3.09	-	3.36	-
Total Long-Term Liabilities	17.74	19.68	18.42	18.75	3.36	-
Total Liabilities	59.46	72.68	44.06	40.58	25.06	19.2
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-in Capital	753.66	751.68	714.98	693.25	531.68	505.72
Accumulated Other Comprehensive Income	-0.04	0.01	0.04	0.22	-1.69	-0.71
Retained Earnings	-693.45	-683.06	-583.56	-456.39	-334.56	-219.12
Shareholders' Equity	60.18	68.64	131.46	237.09	195.44	285.9
Total Liabilities & Equity	119.64	141.32	175.52	277.67	220.5	305.1
Total Debt	17.72	17.79	18.03	20.23	1.83	1.74
Net Cash (Debt)	63.83	85.43	115.59	212.71	199.9	289.49
Net Cash Growth	-25.28%	-26.10%	-45.66%	6.41%	-30.95%	32.61%
Net Cash Per Share	0.81	1.11	1.52	3.52	4.22	6.29
Book Value	60.18	68.64	131.46	237.09	195.44	285.9
Book Value Per Share	0.77	0.89	1.73	3.93	4.13	6.21
Tangible Book Value	60.18	68.64	131.46	237.09	195.44	285.9
Tangible Book Value Per Share	0.77	0.89	1.73	3.93	4.13	6.21

SEC Filings: 10-K · 10-Q